Form 4: DiaMedica Therapeutics Director Acquires Shares and Stock Options
SEC Form 4 Filing
Director James T. Parsons acquires shares and stock options in DiaMedica Therapeutics Inc.
Summary
- On January 2, 2025, James T. Parsons, a director of DiaMedica Therapeutics Inc., acquired 15,917 voting common shares at a price of $5.34 per share.
- These shares are issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000.
- The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.
- Parsons also acquired 4,287 stock options with an exercise price of $5.51, vesting in two nearly equal installments on March 1, 2025, and June 1, 2025.
- Following these transactions, Parsons beneficially owns 75,854 voting common shares and 4,287 stock options.
- The stock options expire on January 1, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine transaction.
Positives
- A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such transactions can provide insights into management's sentiment regarding the company's prospects.
Comparison to Industry Standards
- Comparing the vesting schedules and exercise prices of these options to those of similar companies in the biotechnology sector would provide a benchmark for assessing their attractiveness.
- For example, companies like BioMarin Pharmaceutical or Vertex Pharmaceuticals often grant stock options to directors and executives as part of their compensation packages.
- Analyzing the terms of those grants relative to DiaMedica's can offer a comparative perspective.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Acquisition of shares and stock options |
| 01/03/2025 | Date of Form 4 filing |
| 03/01/2025 | First vesting date for stock options |
| 03/31/2025 | First vesting date for deferred stock units |
| 06/01/2025 | Second vesting date for stock options |
| 06/30/2025 | Second vesting date for deferred stock units |
| 09/30/2025 | Third vesting date for deferred stock units |
| 12/31/2025 | Fourth vesting date for deferred stock units |
| 01/01/2035 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.